Skip to main content
. 2024 Mar 4;17(3):e13744. doi: 10.1111/cts.13744

FIGURE 1.

FIGURE 1

Study design. Fasted, vutiglabridin 480 mg administration in fasted state; Low‐Fat, vutiglabridin 480 mg administration after the intake of low‐fat meal (total 500–600 kcal, fat content 100–125 kcal); High‐Fat, vutiglabridin 480 mg administration after the intake of high‐fat meal (total 800–1000 kcal, fat content 500–600 kcal); PK, pharmacokinetic.